All In Biotech

Drug Trial Radar · NCT05794139

Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy

A Phase 2, Randomised, Double-blind, Placebo-controlled, 2-way Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 in Ambulatory Adults With Type 3 Spinal Muscular Atrophy

Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

52

Actual

Start

Sep 21, 2023

Primary completion

May 11, 2026

Study completion May 18, 2026

Sponsor

Lead sponsor
NMD Pharma A/SIndustry
Sponsor type
Industry
First posted
Apr 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of NMD670 in the treatment of ambulatory adults with spinal muscular atrophy type 3

Conditions

  • Spinal Muscular Atrophy

Interventions

  • NMD670Drug

    Tablets

  • PlaceboDrug

    Tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in 6 minute walk test (6MWT) total distance versus placeboTime frame: Baseline to day 21

Locations

25 sites in 8 countries. Site status is shown where the registry gives one.

  • UCLA David Geffen School Of Medicine - Neurology

    Los Angeles, California

  • Stanford University Medical Center

    Palo Alto, California

  • University of Kansas Medical Center

    Kansas City, Kansas

  • The Johns Hopkins Medicine, Spinal Muscular Atrophy Center

    Baltimore, Maryland

  • Roy Blunt NextGen Precision Health Institute

    Columbia, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Rare Disease Research - Raleigh-Durham

    Hillsborough, North Carolina

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • Neurology Rare Disease Center

    Denton, Texas

  • UZ Leuven - Neurochirurgie Campus Gasthuisberg

    Leuven, Belgium

  • CHR de la Citadelle - Neurologie

    Liège, Belgium

  • Heritage Medical Research Clinic

    Calgary, Canada

  • Genge Partners Inc.

    Montreal, Canada

  • Aarhus Universitetshospital, Neurologisk Afdeling

    Aarhus, Denmark

  • Rigshospitalet - Neurologisk Afdeling

    Copenhagen, Denmark

  • Charite - Campus Virchow-Klinikum (CVK)

    Berlin, Germany

  • Universitätsklinikum Essen - Klinik Für Neurologie

    Essen, Germany

  • Istituto Giannina Gaslini, IRCCS

    Genova, Italy

  • Istituto Neurologico C. Besta, Fondazione IRCCS

    Milan, Italy

  • Ospedale Niguarda, ASST Grande Ospedale Metropolitano Niguarda

    Milan, Italy

  • AOU Città della Salute e della Scienza di Torino

    Torino, Italy

  • Universitair Medisch Centrum Utrecht, locatie Academisch Zie - Neurology

    Utrecht, Netherlands

  • Hospital Universitari Vall D Hebron

    Barcelona, Spain

  • Hospital Materno Infantil La Paz

    Madrid, Spain

  • Hospital Universitario y Politécnico La Fe

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.